The Treatment of Chronic Bacterial Prostatitis: Principles and Management
Chronic bacterial prostatitis (CBP) is a subtle disease, often insidious in its onset, that challenges the acumen as well as the patience and determination of every urologist, when it comes to cure this disease. However, CBP is a clinical entity accurately defined by two basic features: recurrent urinary tract infections (UTIs) and persistence of gram-negative enterobacteria, mainly Escherichia coli, in the prostatic secretion. CBP is probably the most common cause of recurrent UTIs in the male patient because the bacterial pathogen often persists unaltered in the prostatic secretion during antibacterial therapy, frequently insufficient and inadequate, and eventually reinfects the urine after treatment is withdrawn. CBP is mainly a bacteriologic diagnosis and, therefore, sequential bacteriologic localization cultures of the initially voided urine, the midstream urine, and the expressed prostatic secretion (EPS) are essential in reaching the right diagnosis and cannot be replaced by any other method. Demonstration of gram-negative bacteria in the EPS in the presence of sterile initial and midstream urine cultures are highly diagnostic for CBP. Alternatively, a significantly higher bacterial level (of a log or more) in the EPS compared to the initial urethral specimen is also considered diagnostic of CBP.
KeywordsAntibacterial Treatment Prostatic Epithelium Retropubic Prostatectomy Chronic Bacterial Prostatitis Recurrent UTIs
Unable to display preview. Download preview PDF.
- Cox CE (1989) Ofloxacin in the management of complicated urinary tract infections, including prostatitis. Am J Med 87 Suppl 6C: 61S–68SGoogle Scholar
- Gombert ME, du Bouchet L, Audicino TM, Berkowitz LB, Macchia RJ (1987) Brief report: prostatic tissue concentrations of ciprofloxacin after oral administration. Am J Med 82 Suppl 4A: 130–132Google Scholar
- Larsen EH, Gasser TC, Dørflinger T, Madsen PO (1986) The concentrations of various quinolone derivatives in the human prostate. In: Weidner W, Brunner H, Krause W, Rothauge CF (eds) Therapy of prostatitis: experimental and clinical data. Zuckschwerdt Munich, pp 40–44Google Scholar
- Meares EM Jr (1975) Long-term therapy of chronic bacterial prostatitis with trimethoprim-sulfamethoxazole. Can Med Assoc J 112 Suppl: 22S–25SGoogle Scholar
- Meares EM Jr (1986) Chronic bacterial prostatitis: role of transurethral prostatectomy (TURP) in therapy. In: Weidner W, Brunner H, Krause W, Rothauge CF (eds) Therapy of prostatitis: experimental and clinical data. Zuckschwerdt, Munich, pp 193–197Google Scholar
- Naber KG (1989) The role of quinolones in the treatment of chronic bacterial prostatitis. Infection 19 Suppl 3: S170–S177Google Scholar
- Naber KG, Sörgel F, Kees F, Jaehde U, Schumacher H (1989) Pharmacokinetics of ciprofloxacin in young (healthy volunteers) and elderly patients, and concentrations in prostatic fluid, seminal fluid and prostatic adenoma tissue following intravenous administration. Am J Med 87 Suppl 5A: 57S–59SGoogle Scholar
- Pfau A (1991) The treatment of chronic bacterial prostatitis. Infection 19 Suppl 3: S160–S164Google Scholar
- Sabbay J, Hoagland VL, Cook T (1986) Norfloxacin versus cotrimoxazole in the treatment of recurring urinary tract infections in men. Scand J Infect Dis Suppl 48: 48–53Google Scholar
- Stamey TA (1980) Urinary infections in males. In: Stamey TA (ed) Pathogenesis and treatment of urinary tract infections. Williams and Wilkins, Baltimore, pp 342–29Google Scholar
- Stamey TA, Bushby SRM, Bragonje J (1973) The concentration of trimethoprim in prostatic fluid: Nonionic diffusion or active transport? J Infect Dis 128 Suppl: S686–S690Google Scholar